Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparison of the Efficacy and Safety of New Platform Everolimus-eluting Coronary Stent System (Promus Element) With Zotarolimus-eluting Coronary Stent System (Endeavor Resolute) and Triple Anti-platelet Therapy With Double-dose Clopidogrel Anti-platelet Therapy in Patients With Coronary Heart Disease.

Next Previous
Trial Profile

Comparison of the Efficacy and Safety of New Platform Everolimus-eluting Coronary Stent System (Promus Element) With Zotarolimus-eluting Coronary Stent System (Endeavor Resolute) and Triple Anti-platelet Therapy With Double-dose Clopidogrel Anti-platelet Therapy in Patients With Coronary Heart Disease.

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 08 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Everolimus (Primary) ; Aspirin; Cilostazol; Clopidogrel; Zotarolimus
  • Indications Coronary artery disease; Coronary artery restenosis; Embolism and thrombosis
  • Focus Therapeutic Use
  • Acronyms HOST-ASSURE

Most Recent Events

  • 16 Dec 2013 Planned end date changed from 1 Dec 2012 to 1 Jun 2015 as reported by ClinicalTrials.gov record.
  • 09 Mar 2013 Primary endpoint results for the everolimus versus zotaralimus-eluting stent comparison presented at the 62nd Annual Scientific Session of the American College of Cardiology.
  • 25 Apr 2012 Results for the triple versus double-dose antiplatelet therapy comparison presented at the 61st Annual Scientific Session of the American College of Cardiology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top